COGT News and Press, Cogent Biosciences Inc Com From 09/13/22

Summary Today, we put Cogent Biosciences, Inc. in the spotlight for the first time in nearly two years. Cogent stock has roughly tripled since positive trial data came out in June, and the company has addressed its current funding needs. More upside ahead? An investment analys...

Gainers: Blue Water Vaccines ( BWV ) +57% . Eargo ( EAR ) +49% . Cassava Sciences ( SAVA ) +29% . MiNK Therapeutics ( INKT ) +24% . Cogent Biosciences ( COGT ) +16% . Losers: Blueprint Medicines ( BPMC ) -22% ....

Cogent Biosciences press release ( NASDAQ: COGT ): Q2 GAAP EPS of -$0.71 misses by $0.05 . As of June 30, 2022, cash and cash equivalents were $325.6 million, as compared to $191.0 million as of March 31, 2022. The company believes that its cash and cash equivalen...

On-track to present additional data from Phase 2 APEX trial by the end of 2022 Initial data from Phase 2 SUMMIT trial & lead-in data from Phase 3 PEAK trial planned for 1H23 Ended 2Q 2022 with $325.6 million , including $172.6 million in gross proceeds from J...

Cogent has a single molecule in various trials. Recently, they produced some positive early data. We should be able to get a better grasp on the company in about a year. For further details see: Cogent Biosciences: APEX Data Was Interesting, But We Need More

Up 120.4% to $9.61, Cogent Biosciences Inc. (NGS:COGT), is one of today's notable movers. In the past 52 weeks, Cogent Biosciences Inc. share prices are bracketed by a low of $3.79 and a high of $11.06 and is now at $9.61, 154% above that low price. Receive IBN Spotlights - "Bite Size"...

One of today's notable stocks on the rise is Cogent Biosciences Inc. (NGS:COGT), up 116.7% to $9.45. In the past 52 weeks, shares of Cogent Biosciences Inc. have traded between a low of $3.79 and a high of $11.06 and is now at $9.45, which is 149% above that low price. Receive IBN Spot...

CAMBRIDGE, Mass. and BOULDER, Colo., June 16, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the closing of its upsized underwritten public offering of ...

Cogent Biosciences (NASDAQ:COGT) priced an underwritten public offering of 15.17M shares offered at a public offering price of $8.25/share. The company is also offering pre-funded warrants to purchase 3.03M shares at a purchase price of $8.24/pre-funded warrant. Underwriters granted 30-d...

CAMBRIDGE, Mass. and BOULDER, Colo., June 13, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the pricing of an underwritten public offering of 15,169,69...